Pharmahungary is a global provider of innovative preclinical (nonclinical) and clinical R&D solutions for pharmaceutical, biotech and food supplement companies, focusing on cardiovascular (cardiovasc™, www.cardiovasc.com) and metabolic diseases such as diabetes, hyperlipidemia, atherosclerosis, obesity and aging. Our know-how in custom design innovative R&D model systems (innoRD™) significantly reduces the duration of your preclinical drug development. Special risk sharing opportunities are available. Pharmahungary’s high quality services are based on highly trained (in the US, Canada, UK, Germany) management team with recognized international expertise in preclinical and clinical pharmacology and medical sciences.

Pharmahungary runs in-house R&D projects for the diagnosis and therapy of cardiovascular and metabolic diseases, currently focusing on the development of inhibitors of peroxynitrite (nitroscience™ project) and its downstream cellular targets matrix metalloproteinases (MMPharma™ project), activators of biglycan (biglycan™ project) for cardiovascular indications such as ischemic heart disease and atherosclerosis, as well as innovative stem-cell based assays (innostem™ project). Pharmahungary intends to outlicense its new technologies and seeking for co-development partners.

Pharmahungary™ is a member of the Hungarian Biotechnology Association.

Please contact us by e-mail or fax. Due to the large number of unsolicited phone calls, we take phone calls scheduled by prior e-mail correspondence only. Thank you for your understanding.

Pharmahungary does not distribute bulk e-mails. However, unauthorized use of virtual pharmahungary.com e-mail addresses for distribution of illegal spams has been experienced. Pharmahungary is not responsible for such illegal spams.